CN119613553A - 肿瘤治疗剂及其应用 - Google Patents

肿瘤治疗剂及其应用 Download PDF

Info

Publication number
CN119613553A
CN119613553A CN202411010644.9A CN202411010644A CN119613553A CN 119613553 A CN119613553 A CN 119613553A CN 202411010644 A CN202411010644 A CN 202411010644A CN 119613553 A CN119613553 A CN 119613553A
Authority
CN
China
Prior art keywords
seq
cdr2
chain cdr1
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411010644.9A
Other languages
English (en)
Chinese (zh)
Inventor
徐刚
陈博
王莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Connaught Biomedical Technology Chengdu Co ltd
Original Assignee
Connaught Biomedical Technology Chengdu Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Biomedical Technology Chengdu Co ltd filed Critical Connaught Biomedical Technology Chengdu Co ltd
Publication of CN119613553A publication Critical patent/CN119613553A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202411010644.9A 2019-04-19 2020-04-15 肿瘤治疗剂及其应用 Pending CN119613553A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019103156349 2019-04-19
CN201910315634 2019-04-19
PCT/CN2020/084991 WO2020211792A1 (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用
CN202080028880.7A CN113748133B (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080028880.7A Division CN113748133B (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用

Publications (1)

Publication Number Publication Date
CN119613553A true CN119613553A (zh) 2025-03-14

Family

ID=72837018

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411010644.9A Pending CN119613553A (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用
CN202080028880.7A Active CN113748133B (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080028880.7A Active CN113748133B (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用

Country Status (5)

Country Link
US (1) US20220372112A1 (enExample)
EP (1) EP3960766A4 (enExample)
JP (3) JP2022529703A (enExample)
CN (2) CN119613553A (enExample)
WO (1) WO2020211792A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
CN114366818B (zh) * 2020-10-15 2025-02-25 上海美雅珂生物技术有限责任公司 抗体药物偶联物及其应用
EP4299593A4 (en) * 2021-04-02 2025-12-10 Oricell Therapeutics Co Ltd CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE
JP2024540062A (ja) 2021-11-05 2024-10-31 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 抗ｃｌｄｎ１８．２抗体及びその用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025088105A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd Cancer treatment with anti-claudin 18.2 adc
WO2025086270A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd. Cancer treatment with anti-claudin 18.2 adc
WO2025086268A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd. Cancer treatment with anti-claudin 18.2 adc
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US10093736B2 (en) * 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP7587921B2 (ja) * 2016-07-08 2024-11-21 クレージュ メディカル カンパニー，リミテッド 抗クローディンタンパク質１８ａ２の抗体及びその応用

Also Published As

Publication number Publication date
CN113748133A (zh) 2021-12-03
EP3960766A4 (en) 2022-12-07
JP7547581B2 (ja) 2024-09-09
JP2024167313A (ja) 2024-12-03
JP2023153984A (ja) 2023-10-18
WO2020211792A1 (zh) 2020-10-22
US20220372112A1 (en) 2022-11-24
CN113748133B (zh) 2024-07-02
JP2022529703A (ja) 2022-06-23
EP3960766A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
JP7547581B2 (ja) 腫瘍治療薬及びその応用
CN110577597B (zh) 一种阻断CD47和SIRPα相互作用的抗体
CN111454357B (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
CN113166246B (zh) 一种抗体及其用途
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
CN111171155B (zh) 抗cd3和cd123双特异性抗体及其用途
US20240117035A1 (en) Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors
JP7734386B2 (ja) 医薬組成物、その製造方法及び用途
KR102444797B1 (ko) α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도
CN116547300B (zh) 双特异性抗体及其应用
WO2024002308A1 (zh) 一种新型多特异肿瘤抑制剂的开发和应用
CN118240092A (zh) 一种抗pd-l1和tigit双特异性抗体融合蛋白及其应用
CN118580373A (zh) 一种TGF-β和TIGIT双特异性融合蛋白及其用途
CN118240091A (zh) 一种抗pd-l1和tigit双特异性抗体及其应用
HK40075930A (en) TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN
HK40048164A (en) Antibody and use thereof
HK1225285A1 (en) Novel anti adam17 antibody and its use for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination